Completed PHASE2 INTERVENTIONAL 1-arm NCT00714025

A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy

A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma After Failure of Platinum-based Chemotherapy

Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Conditions Transitional Cell Carcinoma

Interventions RAD001

Updated 6 times since 2017 Last updated: Jan 23, 2012 Started: Nov 30, 2008 Primary completion: Apr 30, 2009 Completion: Jan 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Transitional Cell Carcinoma, this trial is completed. The trial is conducted by Cliniques universitaires Saint-Luc- Université Catholique de Louvain and has accumulated 6 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Data source: Cliniques universitaires Saint-Luc- Université Catholique de Louvain

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Brussels, Belgium